The Center for Genetic Engineering and Biotechnology (CIGB) signed five contracts, two of them with the Turkish company Hasbiotech, for the commercialization of the Cuban medicine Heberprot-P, to treat diabetic foot ulcers.
Likewise, with the same entity, it signed an agreement for the constitution of a joint venture in the western Mariel Special Development Zone for the development of innovative products.
For this same purpose, the CIGB signed a letter of intent with the Raydel Korea entity, from South Korea, and another with the Cypress View Land & Cattle Corporation, of Canada, for the production of grains using biotechnological techniques.
The National Center for Scientific Research, for its part, established an international sales contract with the company Rainbow Nature Pty, from Australia.
Likewise, the Center for Molecular Immunology strengthened ties with Russia after signing an agreement for the commercialization of the Cuban product Nimotuzumab, used in cancer patients.
For its part, the National Center for Biopreparations established an alliance for the international sale of national drugs Trofim and Biomodulina-T with the Dominican Republic.
According to Rolando Pérez, scientific secretary of the event’s organizing committee, the BioHabana congress was characterized by its diversity and breadth.
We had the assistance of more than a thousand national and foreign delegates, 108 virtual participants, 334 speakers, more than 200 foreign guests from 51 countries and representatives from all regions of the country, he summarized.
He highlighted the importance of the issues associated with the results of the Cuban vaccine against lung cancer CIMAvax-EGF, and the development of anti-Covid-19 immunizers formulated in Cuba (Soberana 02, Soberana Plus and Abdala), and the effectiveness shown by the still candidates Soberana 01 and Mambisa.
During the congress, which was held from last Monday until today at the Havana Convention Center, topics associated with medical technology and industry 4.0, chronic inflammation, cancer and autoimmunity, agricultural biotechnology and brain diseases were discussed.
At the closing ceremony, the call for BioHabana 2024 was left open.
ef/oda/ifs
